Spruce Biosciences Q1 2025 10-Q Filed
Ticker: SPRB · Form: 10-Q · Filed: May 6, 2025 · CIK: 1683553
| Field | Detail |
|---|---|
| Company | Spruce Biosciences, Inc. (SPRB) |
| Form Type | 10-Q |
| Filed Date | May 6, 2025 |
| Risk Level | medium |
| Sentiment | neutral |
Sentiment: neutral
Topics: 10-Q, financials, debt, fair-value
Related Tickers: SVB
TL;DR
**SPRUCE BIOSCIENCES Q1 2025 10-Q FILED: Financials, warrants, and loan details updated.**
AI Summary
Spruce Biosciences, Inc. filed its 10-Q for the period ending March 31, 2025. The company reported on its financial position, including its money market fund investments and warrant liabilities, which are measured at fair value. Spruce Biosciences also detailed its term loan with Silicon Valley Bank, originally established on September 30, 2019, and noted the Allievex Purchase Agreement, with a maximum amount specified as of March 31, 2025.
Why It Matters
This filing provides insight into Spruce Biosciences' financial health and ongoing operational agreements, which are crucial for investors to assess the company's stability and future prospects.
Risk Assessment
Risk Level: medium — The filing details financial instruments and loan agreements, indicating potential financial risks and operational complexities for Spruce Biosciences.
Key Numbers
- 2025-03-31 — Reporting Period End (Financials and fair value measurements are as of this date.)
- 2019-09-30 — Term Loan Origination (Date the term loan with Silicon Valley Bank was established.)
Key Players & Entities
- Spruce Biosciences, Inc. (company) — Filer
- Silicon Valley Bank (company) — Lender for Term Loan
- Allievex Purchase Agreement (company) — Key agreement mentioned
- HBM Alpha Therapeutics Inc (company) — Mentioned in context of Q1 2025
- March 31, 2025 (date) — Reporting period end date
- September 30, 2019 (date) — Original establishment date of Term Loan
FAQ
What is the current status of Spruce Biosciences' money market fund investments?
As of March 31, 2025, Spruce Biosciences' money market fund investments are reported under fair value measurements, categorized with Level 2 and Level 3 inputs.
What is the nature of the Allievex Purchase Agreement mentioned in the filing?
The Allievex Purchase Agreement is referenced with a maximum amount specified as of March 31, 2025, and was also noted in the period of November 1-30, 2024.
What are the details of the term loan with Silicon Valley Bank?
Spruce Biosciences has a term loan with Silicon Valley Bank, originally established on September 30, 2019, with details relevant to the period of January 1, 2025, to March 31, 2025, including minimum and maximum terms.
How are Spruce Biosciences' warrant liabilities valued?
The company's warrant liabilities are measured at fair value on a recurring basis, with reporting as of March 31, 2025.
What is Spruce Biosciences' fiscal year end?
Spruce Biosciences' fiscal year ends on December 31.
Filing Details
This Form 10-Q (Form 10-Q) was filed with the SEC on May 6, 2025 regarding SPRUCE BIOSCIENCES, INC. (SPRB).